Head-to-head evidence
ASC30 vs GZR18
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
ASC30
Developed by Ascletis Pharma
NCT07002905 · Phase 2 · completed
The study randomly assigned 125 participants and used quadruple blinding with placebo control across seven cohorts. Its primary endpoint was percent change in body weight at Week 13, but the registry has not posted whether this endpoint was met.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: July 2028 · NCT07743450 (registry estimate)
GZR18
Developed by Gan & Lee Pharmaceuticals
NCT06737042 · Phase 2 · completed
The study randomized 326 participants and used quadruple masking with placebo and tirzepatide comparator arms; its primary endpoint was the clinical outcome of percentage change in body weight. Because the primary comparison has not yet been reported, it cannot establish whether GZR18 met its efficacy objective.
Next expected readout: June 2027 · NCT07150975 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · GZR18's landscape